BTG Pactual Asset Management US LLC Purchases New Shares in OR Royalties Inc. $OR

BTG Pactual Asset Management US LLC purchased a new stake in OR Royalties Inc. (NYSE:OR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 29,400 shares of the basic materials company's stock, valued at approximately $930,000.

Several other large investors have also bought and sold shares of OR. Public Employees Retirement System of Ohio acquired a new position in shares of OR Royalties in the 2nd quarter valued at $1,599,000. Parvin Asset Management LLC acquired a new stake in OR Royalties in the 2nd quarter valued at approximately $2,180,000. Bank of New York Mellon Corp acquired a new position in OR Royalties during the second quarter worth $1,572,000. Grove Bank & Trust bought a new position in OR Royalties in the second quarter valued at approximately $32,000. Finally, Groupe la Francaise raised its position in OR Royalties by 122.2% during the first quarter. Groupe la Francaise now owns 200,000 shares of the basic materials company's stock worth $7,591,000 after acquiring an additional 110,000 shares in the last quarter. 68.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on OR. Weiss Ratings cut OR Royalties from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, July 24th. Jefferies Financial Group lowered their target price on OR Royalties from $40.00 to $34.00 and set a "hold" rating on the stock in a research note on Monday, July 6th. Royal Bank Of Canada decreased their price objective on shares of OR Royalties from $50.00 to $45.00 and set an "outperform" rating on the stock in a research note on Thursday, July 9th. Wall Street Zen downgraded OR Royalties from a "buy" rating to a "hold" rating in a report on Saturday, June 6th. Finally, Scotiabank reduced their target price on shares of OR Royalties from $51.00 to $42.00 and set a "sector perform" rating on the stock in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $40.50.

OR Royalties Trading Down 1.3%

NYSE:OR opened at $36.93 on Tuesday. OR Royalties Inc. has a 12 month low of $27.54 and a 12 month high of $48.06. The stock has a market capitalization of $6.88 billion, a PE ratio of 24.62 and a beta of 0.75. The company has a current ratio of 2.28, a quick ratio of 2.28 and a debt-to-equity ratio of 0.14. The firm's 50 day moving average is $31.93 and its 200 day moving average is $36.40.

OR Royalties (NYSE:OR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The basic materials company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.01. OR Royalties had a net margin of 78.04% and a return on equity of 16.41%. The firm had revenue of $97.82 million for the quarter, compared to the consensus estimate of $97.93 million. Sell-side analysts expect that OR Royalties Inc. will post 1.25 earnings per share for the current year.

OR Royalties Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Wednesday, September 30th will be issued a $0.065 dividend. This represents a $0.26 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. OR Royalties's dividend payout ratio is presently 16.67%.

OR Royalties Company Profile

OR Royalties PLC NYSE: OR is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company's core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source